Post by Sartorius | Bioprocess Solutions

Our newly launched genetically engineered #CHO host cell line supports more efficient manufacturing by delivering higher titers while maintaining critical quality attributes across multiple molecule types and manufacturing formats. 🧬 These gains can help reduce cost per dose and improve access to affordable biologics through traditional fed-batch and intensified manufacturing processes.    In 14-day fed-batch processes using 5 L bioreactors, the engineered host achieved nearly 2x higher titers across expression of two different mAbs and one Fc-fusion protein compared with the wild type.    The new host also demonstrated improved productivity in an IgG4 perfusion process over 27 days, with up to 2x higher daily titers relative to the wild type, demonstrating strong performance in continuous bioprocessing applications.    🔎 Learn more about our new CHO cell line and how it could strengthen your biologics production.🔗https://sar.to/mmvzp #SimplifyingProgress #InThisTogether #CLD #CellLineDevelopment